REGENXBIO

REGENXBIO is facing a securities investigation due to potential violations of federal securities laws. The FDA placed clinical holds on its RGX-111 and RGX-121 programs, leading to a significant decline in its share price. The company's CEO, Curran Simpson, is also under scrutiny for potentially misleading statements during a Q3 2025 earnings call.

REGENXBIO is facing a class action lawsuit for allegedly misleading investors about the viability of its drug candidate RGX-111. The FDA placed a clinical hold on RGX-111 and RGX-121 due to safety concerns, leading to a significant drop in REGENXBIO's stock price.

REGENXBIO is facing a class action securities lawsuit due to alleged securities fraud related to its RGX-111 gene therapy. The lawsuit claims the company made misleading statements about the efficacy and safety of RGX-111, leading to a significant drop in its stock price after the FDA placed a clinical hold on the therapy.

REGENXBIO is facing a class action lawsuit after the United States===Food and Drug Administration placed a clinical hold on its investigational gene therapies, RGX-111 and RGX-121. This news caused REGENXBIO's stock price to fall significantly, indicating negative market sentiment and potential financial repercussions from the lawsuit.

REGENXBIO is facing a class action lawsuit due to allegedly disseminating false and misleading statements regarding the efficacy and safety of its RGX-111 trial study. The U.S. Food & Drug Administration placed a clinical hold on RGX-111 after an intraventricular CNS tumor was found in a participant, causing REGENXBIO's stock price to fall by nearly 18%.